Search Results

Now showing 1 - 4 of 4

Some of the metrics are blocked by your
consent settings
Galectin-3 as a Biomarker of Disease Severity in Acute-on-Chronic Liver Failure
(2020)
Cervantes-Álvarez, Eduardo
;
Limón-de la Rosa, Nathaly
;
Vilatoba, Mario
;
Pérez-Monter, Carlos
;
Hurtado-Gómez, Sahara
*Purpose: A matter of great importance is the discovery of alternative diagnostic measures that can detect liver disease at an early stage, especially when at risk of developing acute on chronic liver failure (ACLF), to optimize outcome and survival. Galectin-3 (Gal-3) is a lectin that binds to β-galactosides and can be secreted to the systemic circulation, regulating inflammation and fibrosis. Due to its direct role in inflammation and fibrosis, levels of this lectin can reflect the progression of liver damage and the possible consequent multiorgan failure, which is a distinctive characteristic of ACLF. The purpose of this study is to determine if liver Gal-3 expression is a useful biomarker of disease progression. *Methods: Liver samples from cirrhotic patients with compensated, decompensated cirrhosis and ACLF were collected at the time of liver transplant. The liver from donors was used as controls. RNA was extracted and liver Gal-3 expression was analyzed by quantitative polymerase chain reaction (qPCR). The values obtained were correlated with clinical and biochemical parameters using Pearson’s and Spearman’s correlation coefficients. A comparison among 3 different groups was performed using the Kruskal-Wallis test with Dunn’s multiple comparisons test.
51 2
Some of the metrics are blocked by your
consent settings
Castleman's Disease : Clinicopathological Characteristics of a Cohort of Hispanic Patients
(2022)
Montante-Montes, Daniel
;
Lizardo-Thiebaud, María José
;
Rodriguez-Rodriguez, Sergio
;
Monroy-Ramos, Cinthya
;
Riveros Gilardi, Berta
Introduction: Castleman Disease (CD) depicts a group of heterogeneous hematologic disorders with characteristic histopathological features. Two forms of CD are recognized,unicentric (UCD) or multicentric (MCD). This classification relies on the number of regions of lymph node involvement. Objetives: To describe the clinicopathological characteristics of a cohort of Hispanic patients with Castleman's Disease. Material: Patients with CD diagnosis that were followed at the Monoclonal Gammopathies Clinic in INCMNSZ, from January 2006 to July 2022 were included.A team of pathologists that included a trained hematopathologist reviewed the biopsies, extended the immunohistochemical panel and classified the cases according to the International, evidence-based consensus diagnostic criteria for HHV8 negative/idiopathic MCD. ©The aurhors.
19 1
Some of the metrics are blocked by your
consent settings
Galectin‐3 is overexpressed in advanced cirrhosis and predicts post‐liver transplant infectious complications
(2022)
Cervantes‐Alvarez, Eduardo
;
Limón-de la Rosa, Nathaly
;
Vilatoba, Mario
;
Pérez Nicomedes, Carlos
;
Hurtado‐Gomez, Sahara
Background & aims: Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin-3 is a β-galactoside-binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin-3 expression in advanced cirrhosis and its ability to predict post-transplant infectious complications. Methods: We collected sera and liver samples from 129 cirrhotic patients at the time of liver transplantation and from an external cohort of 37 patients with alcoholic liver disease including alcoholic hepatitis (AH) at the time of diagnosis. Galectin-3 was assessed by ELISA, real-time PCR, immunohistochemistry and RNA-seq. Receiver operating characteristic curves and Cox proportional-hazards regression analysis were performed to assess the predictive power of galectin-3 for disease severity and post-transplant infections.
Scopus© Citations 14 23 1
Some of the metrics are blocked by your
consent settings
Direct or collateral liver damage in SARS-CoV-2-infected patients
(2020)
Lizardo-Thiebaud, María José
;
Cervantes-Álvarez, Eduardo
;
Limón-de la Rosa, Nathaly
;
Tejeda Domínguez, Farid
;
Palacios-Jiménez, Mildred
Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease. © 2020 American Institute of Physics Inc.. All rights reserved.
Scopus© Citations 24 29 2

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results